Discovery of novel improved tools for diagnosis, prevention and therapy of chronic kidney disease (CKD) is an important task for the nephrology community and it is likely that scientific breakthroughs, to a large extent, will be based on genomics. The rapid growth of the number of genome-wide association studies, major advances in DNA sequencing and omics profiling, and accelerating biomedical research efforts in this area have greatly expanded the knowledge base needed for applied genomics. However, translating and implementing genotype-phenotype data into gene-based medicine in CKD populations is still in an early phase and will require continuous research efforts with integrated approaches and intensified investigations that focus on the biological pathways, which causatively link a genetic variant with the disease phenotype. In this article, we review some current strategies to unravel these translational gaps as well as prospects for the implementation of genetic and epigenetic methods into novel clinical practice.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/ndt/gfu021 | DOI Listing |
Br J Anaesth
January 2025
Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; Center for Anesthesia Research Excellence (CARE), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; Department of Anesthesiology, Medical Faculty and University Hospital Duesseldorf, Heinrich Heine University Duesseldorf, Duesseldorf, Germany. Electronic address:
BMJ Open Gastroenterol
January 2025
Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Objective: To develop and validate a prognostic model for risk-stratified monitoring of 5-aminosalicylate nephrotoxicity.
Methods: This UK retrospective cohort study used data from the Clinical Practice Research Datalink Aurum and Gold for model development and validation respectively. It included adults newly diagnosed with inflammatory bowel disease and established on 5-aminosalicylic acid (5-ASA) treatment between 1 January 2007 and 31 December 2019.
Ann Vasc Surg
January 2025
Division of Vascular Surgery, University of South Florida College of Medicine, Tampa, Florida, USA. Electronic address:
Objective: Frailty has become an increasingly recognized perioperative risk stratification tool. While frailty has been strongly correlated with worsening surgical outcomes, the individual determinants of frailty have rarely been investigated in the setting of aortic disease. The aim of this study was to examine the determinants of an 11-factor modified frailty index (mFI-11) on mortality and postoperative complications in patients undergoing endovascular aortic aneurysm repair (EVAR).
View Article and Find Full Text PDFAm J Kidney Dis
January 2025
Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, USA; Northwestern University Transplant Outcomes Research Collaborative, Comprehensive Transplant Center, Feinberg School of Medicine, Chicago, IL, USA; Centre for Patient Reported Outcomes Research, Department of Applied Health Sciences, University of Birmingham, Edgbaston, Birmingham, UK.
Rationale & Objective: Valid measures of side effects are important to inform clinical use of calcineurin inhibitors (CNIs). This study sought to develop and establish the content validity of a PRO measure to capture side effects among kidney transplant recipients taking CNIs.
Study Design: Qualitative interviews for concept elicitation and cognitive debriefing.
Am J Kidney Dis
January 2025
Renal Division, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; National Taiwan University Hospital Study Group of ARF (NSARF), Taipei, Taiwan.
Rationale & Objective: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve cardiac and kidney outcomes in patients with diabetes; however their efficacy in individuals with reduced estimated glomerular filtration rate (eGFR) is uncertain. This study evaluated the effects of GLP-1RAs on kidney and cardiovascular (CV) outcomes in patients with chronic kidney disease (CKD).
Study Design: Systematic review and meta-analysis of randomized controlled trials (RCTs) reported through May 25, 2024.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!